B. Berner | Semantic Scholar

Once- or twice- daily extended-release metformin was as safe and effective as twice-daily immediate-release meetformin and provided continued glycemic control for up to 24 weeks of treatment.

The transport of buspirone across porcine buccal mucosa in vitro was investigated to elucidate the mechanisms of transport and permeation enhancement and the use of an enhancer combination containing 5% oleic acid, 40% propylene glycol in buffer resulted in the greatest flux.

The in vitropermeability of acyclovir across porcine buccal mucosa and the octanol-water partitioning of the drug were pH dependent, and a model of the paracellular permeation of the anionic, cationic, and zwitterionic forms of acYClovir is consistent with these data.

Transdermal delivery systems, designed on the basis of pharmacokinetic principles and concentration-effect relationships, have the potential to provide optimal therapy for the treatment of some conditions.

Once-daily ciprofloxacin ER was safe, effective, and noninferior to twice- daily ciproprofl oxacin IR in the treatment of acute uUTI and was associated with significantly reduced frequencies of nausea and diarrhea.

Metformin extended release (ER) is a recently approved formulation that provides effective and well-tolerated glycaemic control with once-daily dosing and has similar bioavailability to conventional immediate-release (IR) formulations.

A detailed analysis of the kinetic model proposed by Hansch demonstrates the bilinear form of the model, with the initial slope of the logarithm of the concentration for 50% receptor binding versus log P having a slope of greater than one.